New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis

British Journal of Pharmacology

Volumn 147, Issue 1, 2006, Pages 83-91

  Ligresti, Alessia ^a   Cascio, Maria Grazia ^a   Pryce, Gareth ^b   Kulasegram, Sanjitha ^c   Beletskaya, Irina ^d   De Petrocellis, Luciano ^a   Saha, Bijali ^c   Mahadevan, Anu ^c   Visintin, Cristina ^b   Wiley, Jenny L ^d   Baker, David ^b   Martin, Billy R ^d   Razdan, Raj K ^c   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ORGANIX INC   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 arachidonoylglycerol; Cannabinoid; Endocannabinoid; Membrane transport; Multiple sclerosis; Spasticity

Indexed keywords

ANANDAMIDE; ENDOCANNABINOID; O 2093; O 2247; O 2248; O 3246; O 3262;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; BIOASSAY; CELL MEMBRANE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG UPTAKE; HUMAN; HUMAN CELL; HYDROLYSIS; HYPOTHERMIA; IC 50; IMMOBILIZATION; IN VITRO STUDY; LOCOMOTION; MAST CELL LEUKEMIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SPASTICITY;

ANIMALS; ARACHIDONIC ACIDS; CELL LINE; DISEASE MODELS, ANIMAL; MICE; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; NEUROMUSCULAR BLOCKING AGENTS; POLYUNSATURATED ALKAMIDES; RATS;

EID: 30344432108     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706418     Document Type: Article

References (38)

1. ABDEL-MAGID, A.F., CARSON, K.G., HARRIS, B.D., MARYANOFF, C.A. & SHAH, R.D. (1996). Reductive animation of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive animation procedures. J. Org. Chem., 61, 3849-3862.
2. BAKER, D., PRYCE, G., CROXFORD, J.L., BROWN, P., PERTWEE, R.G., HUFFMAN, J.W. & LAYWARD, L. (2000). Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature, 404, 84-87.
3. BAKER, D., PRYCE, G., CROXFORD, J.L., BROWN, P., PERTWEE, R.G., MAKRIYANNIS, A., KHANOLKAR, A., LAYWARD, L., FEZZA, F., BISOGNO, T. & DI MARZO, V. (2001). Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J., 15, 300-302.
4. BISOGNO, T., MAURELLI, S., MELCK, D., DE PETROCELLIS, L. & DI MARZO, V. (1997). Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem., 272, 3315-3323.
5. BISOGNO, T., MACCARRONE, M., DE PETROCELLIS, L., JARRAHIAN, A., FINAZZI-AGRO, A., HILLARD, C. & DI MARZO, V. (2001). The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur. J. Biochem., 268, 1982-1989.
6. BROOKS, J.W., PRYCE, G., BISOGNO, T., JAGGAR, S.I., HANKEY, D.J., BROWN, P., BRIDGES, D., LEDENT, C., BIFULCO, M., RICE, A.S., DI MARZO, V. & BAKER, D. (2002). Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur. J. Pharmacol., 439, 83-92.
7. CRAVATT, B.F., GIANG, D.K., MAYFIELD, S.P., BOGER, D.L., LERNER, R.A. & GILULA, N.B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 384, 83-87.
8. DE LAGO, E., FERNANDEZ-RUIZ, J., ORTEGA-GUTIERREZ, S., CABRANES, A., PRYCE, G., BAKER, D. & LOPEZ-RODRIGUEZ RAMOS, J.A. (2005). UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur. Neuropsychopharmacol., in press.
9. DE LAGO, E., LIGRESTI, A., ORTAR, G., MORERA, E., CABRANES, A., PRYCE, G., BIFULCO, M., BAKER, D., FERNANDEZ-RUIZ, J. & DI MARZO, V. (2004). In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur. J. Pharmacol., 484, 249-257.
10. DE PETROCELLIS, L., BISOGNO, T., DAVIS, J.B., PERTWEE, R.G. & DI MARZO, V. (2000). Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett., 483, 52-56.
11. DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
12. DI MARZO, V., BIFULCO, M. & DE PETROCELLIS, L. (2004a). The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug. Discov., 3, 771-784, Review.
13. DI MARZO, V., BISOGNO, T., DE PETROCELLIS, L., BRANDI, I., JEFFERSON, R.G., WINCKLER, R.L., DAVIS, J.B., DASSE, O., MAHADEVAN, A., RAZDAN, R.K. & MARTIN, B.R. (2001). Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor 'hybrid' ligands. Biochem. Biophys. Res. Commun., 281, 444-451.
14. DI MARZO, V., FONTANA, A., CADAS, H., SCHINELLI, S., CIMINO, G., SCHWARTZ, J.C. & PIOMELLI, D. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372, 686-691.
15. DI MARZO, V., GRIFFIN, G., DE PETROCELLIS, L., BRANDI, I., BISOGNO, T., WILLIAMS, W., GRIER, M.C., KULASEGRAM, S., MAHADEVAN, A., RAZDAN, R.K. & MARTIN, B.R. (2002). A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J. Pharmacol. Exp. Ther., 300, 984-991.
16. DI MARZO, V., LIGRESTI, A., MORERA, E., NALLI, M. & ORTAR, G. (2004b). The anandamide membrane transporter. Structure-activity relationships of anandamide and oleoylethanolamine analogs with phenyl rings in the polar head group region. Bioorg. Med. Chem., 12, 5161-5169.
17. FEGLEY, D., KATHURIA, S., MERCIER, R., LI, C., GOUTOPOULOS, A., MAKRIYANNIS, A. & PIOMELLI, D. (2004). Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc. Natl. Acad. Sci. U.S.A., 101, 8756-8761.
18. FOWLER, C.J., TIGER, G., LIGRESTI, A., LOPEZ-RODRIGUEZ, M.L. & DI MARZO, V. (2004). Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis - a difficult issue to handle. Eur. J. Pharmacol., 492, 1-11.
19. GLASER, S.T., ABUMRAD, N.A., FATADE, F., KACZOCHA, M., STUDHOLME, K.M. & DEUTSCH, D.G. (2003). Evidence against the presence of an anandamide transporter. Proc. Natl. Acad. Sci. U.S.A., 100, 4269-4274.
20. HAYES, P., MEADOWS, H.J., GUNTHORPE, M.J., HARRIES, M.H., DUCKWORTH, D.M., CAIRNS, W., HARRISON, D.C., CLARKE, C.E., ELLINGTON, K., PRINJHA, R.K., BARTON, A.J., MEDHURST, A.D., SMITH, G.D., TOPP, S., MURDOCK, P., SANGER, G.J., TERRETT, J., JENKINS, O., BENHAM, C.D., RANDALL, A.D., GLOGER, I.S. & DAVIS, J.B. (2000). Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Pain, 88, 205-215.
21. HILLARD, C.J. & JARRAHIAN, A. (2003). Cellular accumulation of anandamide: consensus and controversy. Br. J. Pharmacol., 140, 802-808. Review.
22. HOWLETT, A.C. (2002). The cannabinoid receptors. Prostaglandins Other Lipid Mediat., 68-69, 619-631. Review.
23. HOWLETT, A.C., BREIVOGEL, C.S., CHILDERS, S.R., DEADWYLER, S.A., HAMPSON, R.E. & PORRINO, L.J. (2004). Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology, 47 (Suppl 1), 345-358. Review.
24. LIGRESTI, A., MORERA, E., VAN DER STELT, M., MONORY, K., LUTZ, B., ORTAR, G. & DI MARZO, V. (2004). Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem. J., 380, 265-272.
25. LOPEZ-RODRIGUEZ, M.L., VISO, A., ORTEGA-GUTIERREZ, S., FOWLER, C.J., TIGER, G., DE LAGO, E., FERNANDEZ-RUIZ, J. & RAMOS, J.A. (2003). Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. J. Med. Chem., 46, 1512-1522.
26. MARTIN, B.R., COMPTON, D.R., THOMAS, B.F., PRESCOTT, W.R., LITTLE, P.J., RAZDAN, R.K., JOHNSON, M.R., MELVIN, L.S., MECHOULAM, R. & WARD, S.J. (1991). Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav., 40, 471-478.
27. MCFARLAND, M.J. & BARKER, E.L. (2004). Anandamide transport. Pharmacol. Ther., 104, 117-135. Review.
28. MECHOULAM, R., BEN-SHABAT, S., HANUS, L., LIGUMSKY, M., KAMINSKI, N.E., SCHATZ, A.R., GOPHER, A., ALMOG, S., MARTIN, B.R. & COMPTON, D.R. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 50, 83-90.
29. MELCK, D., BISOGNO, T., DE PETROCELLIS, L., CHUANG, H., JULIUS, D., BIFULCO, M. & DI MARZO, V. (1999). Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem. Biophys. Res Commun., 262, 275-284.
30. MESTRE, L., CORREA, F., AREVALO-MARTIN, A., MOLINA-HOLGADO, E., VALENTI, M., ORTAR, G., DI MARZO, V. & GUAZA, C. (2005). Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem., 92, 1327-1339.
31. ODDI, S., BARI, M., BATTISTA, N., BARSACCHI, D., COZZANI, I. & MACCARRONE, M. (2005). Confocal microscopy and biochemical analysis reveal spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes. Cell. Mol. Life Sci., 62, 386-395.
32. ORTAR, G., LIGRESTI, A., DE PETROCELLIS, L., MORERA, E. & DI MARZO, V. (2003). Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem. Pharmacol., 65, 1473-1481.
33. ORTEGA-GUTIERREZ, S., HAWKINS, E.G., VISO, A., LOPEZ-RODRIGUEZ, M.L. & CRAVATT, B.F. (2004). Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry, 43, 8184-8190.
34. ORTEGA-GUTIERREZ, S., MOLINA-HOLGADO, E., ARÉVALO-MARTÍN, A., CORREA, F., VISO, A., LOPEZ-RODRIGUEZ, M.L., DI MARZO, V. & GUAZA, C. (2005). Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J., 19, 1338-1340.
35. PIOMELLI, D., BELTRAMO, M., GLASNAPP, S., LIN, S.Y., GOUTOPOULOS, A., XIE, X.Q. & MAKRIYANNIS, A. (1999). Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. U.S.A., 96, 5802-5807.
36. SMART, D., GUNTHORPE, M.J., JERMAN, J.C., NASIR, S., GRAY, J., MUIR, A.I., CHAMBERS, J.K., RANDALL, A.D. & DAVIS, J.B. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol., 129, 227-230.
37. SUGIURA, T., KONDO, S., SUKAGAWA, A., NAKANE, S., SHINODA, A., ITOH, K., YAMASHITA, A. & WAKU, K. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 215, 89-97.
38. WILEY, J.L. & MARTIN, B.R. (2003). Cannabinoid pharmacological properties common to other centrally acting drugs. Eur. J. Pharmacol., 471, 185-193.